Hypersensitivity reactions to last generation chimeric, umanized and human recombinant monoclonal antibodies for therapeutic Use

Current Pharmaceutical Design

Volumn 14, Issue 27, 2008, Pages 2883-2891

  Calogiuri, G ^a   Ventura, Mariateresa ^a,b   Mason, L ^c   Valacca, A ^d   Buquicchio, R ^d   Cassano, N ^d   Vena, G A ^d  

^a UNIVERSITY OF BARI   (Italy)

^b Division of Allergology and Clinical Immunology   (Italy)

^c Department of Allergology and Clinical Immunology ^*  (Italy)

^d VITO FAZZI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALPHA INTERFERON; AZATHIOPRINE; BASILIXIMAB; CETUXIMAB; DACLIZUMAB; DIPHENHYDRAMINE; EFALIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ETANERCEPT; FC RECEPTOR; GALACTOSYLGALACTOSE; HISTAMINE; IMMUNOGLOBULIN E; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; NATALIZUMAB; OMALIZUMAB; PARACETAMOL; PLACEBO; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT RESPIRATORY DISTRESS SYNDROME; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTHRALGIA; ASEPTIC MENINGITIS; ATOPIC DERMATITIS; AUTOIMMUNE HEPATITIS; BLEEDING; BRONCHOSPASM; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CROSS REACTION; CYTOKINE RELEASE; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DESENSITIZATION; DISEASE EXACERBATION; DRUG ANTAGONISM; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; DYSPNEA; ECZEMA; EDEMA; EOSINOPHILIA; ERYTHEMA; HEART PALPITATION; HISTAMINE RELEASE; HOT FLUSH; HUMAN; HYPOTENSION; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNE RESPONSE; INFLAMMATION; INJECTION SITE PRURITUS; INJECTION SITE REACTION; LEUKOPENIA; LICHEN PLANUS; LICHENOID ERUPTION; LUPUS LIKE SYNDROME; LYMPHADENOPATHY; MACULOPAPULAR RASH; MALAISE; MAST CELL; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NONHUMAN; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PSORIASIS; REVIEW; SERUM SICKNESS; SIDE EFFECT; SKIN TEST; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; UPREGULATION; URTICARIA; VASCULITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG HYPERSENSITIVITY; HUMANS; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; SKIN TESTS;

EID: 65949120204     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786369786     Document Type: Review

References (113)

1. Kohler G, Millstein C. Continuous cultures of fused cells secreting antibody of prefined specifity. Nature 1975; 256: 495-7.
2. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OTK3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337-42.
3. Gaston RS, Zeierhoi MH, Patterson T, Parsthofer E, Julian BA, Barber WH, et al. OKT3 first dose reaction: Association with T cells subset and cytokines release. Kidney Int 1991; 39: 141-7.
4. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti CD-28 monoclonal antibody TGN 1412. N Engl J Med 2006; 355: 1018-28.
5. Frodin JE, Levfert AK, Mellstedt H. The clinical significance of HAMA in patients treated with mouse monoclonal antibodies. Cell Biophys 1992; 21: 153-65.
6. Chatenoud L, Baudrihaye MF, Chkoff N, Kreis H, Goldstein G, Bach JF. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT-3. J Immunol 1986; 137: 830-8.
7. Legouffe E, Liautard J, Gaillard JP, Rossi JF, Wijdenes J, Bataille R, et al. Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6. Clin Exp Immun 1994; 98: 323-9.
8. Blanco I, Kawatsu R, Harrison K, Leichner P, Augustine S, Baranowska-Kortylewicz J, et al. Anti-idiotypic response against murine monoclonal antibodies reactive with tumor associated antigen TAG-72. J Clin Immunol 1997; 17: 96-106.
9. Nelson RP, Ballow M. Immunomodulation and immunotherapy: Drugs, cytokines, cytokines receptors and antibodies. J Allergy Clin Immunol 2003; 111: S720-32.
10. Baca M, Presta LG, O'Connors SJ, Wells JA. Antibody humanization using monovalent phage display. J Biol Chem 1997; 272: 10678-84.
11. Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, et al. Humanization of an antibody directed against IgE. J Immunol 1993; 151: 2623-32.
12. Cothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, et al. Conformations of immunoglobulin hypervariable regions. Nature 1989; 342: 877-83.
13. Cothia C, Lesk AM. Canonical structure for the hypervariable regions of immunoglobulins. J Mol Biol 1987; 196: 901-17.
14. Foote J, Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol 1992; 224: 487-99
15. Steinitz M, Klein G, Kaskimies S, Makel O. EB virus-induced B lymphocyte cell lines producing specific antibody. Nature 1977; 269: 420-2.
16. Pichler WJ. Adverse side effects to biological agents. Allergy 2006; 61: 912-20.
17. Hommes DW, Van Deventer SJH. Infliximab therapy in Crohn disease: Safety issue. Neth J Med 2003; 6: 100-4.
18. Madan M, Berkowitz SD, Tchen JE. Glycoprotein IIb-IIIa integrin blockade. Circulation 1998; 98: 2629-35.
19. Dery JP, Braden GA, Lincoff AM, Kereiackes DJ, Browne K, Little T, et al. ReoPro readministration registry investigators. Final results of the ReoPro readministration registry. Am J Cardiol 2004; 93: 979-84
20. Curtis BR, Swyers J, Divgi A, McFarland JG, Aster RH. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 2002; 99: 2054-59.
21. Vergara G, Silvestre JF, Betlloch I, Vela P, Albares MP, Pascual JC. Cutaneous drug eruption to inflximab: Report of 4 cases with interface dermatitis patterns. Arch Dermatol 2002; 138: 1258-9.
22. Devos SA, van den BosscheN, deVos M, Naeyaert JM. Adverse skin reactions to anti TNF-alpha monoclonal antibody therapy. Dermatology 2003; 206: 388-90.
23. Kent PD, Davis JM 3rd, Davis MD, Matteson EL. Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis. Arthritis Rheum 2002; 46: 2257-8.
24. Hunger RE, Hunziker T, Buettiker U, Braathen LR, Yawalkar N. Rapid resolution of toxic epidermal necrolysis with anti TNF-alpha. J Allergy Clin Immunol 2005; 116: 923-4.
25. Battistella M, Rivet J, Bachelez H, Lioté F. Lichen planus associated with etanercept. Br J Dermatol 2008; 158: 188-90.
26. Garcovich S, Manco S, Zampetti A, Amerio P, Garcovich A. Onset of lichen planopilaris during treatment with etanercept. Br J Dermatol 2008; 158: 1161-3.
27. De Simone C, Caldarola G, D'Agostino M, Rotoli M, Capizzi R, Amerio P. Lichenoid reaction induced by adalimumab. J Eur Acad Dermatol Venereol 2008; 22: 626-7.
28. Lowndes S, Darby A, Mead G, Lister A. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol 2002; 13: 1948-50.
29. Moneret-vautrin DA, Morisset M, Vignaud JM, Kanny G. T-cell mediated allergy to abciximab. Allergy 2002; 57: 269-70.
30. McCain ME, Quinet RJ, Davis WE. Etanercept and Infliximab associated with cutaneous vasculitis. Br J Rheum 2002; 41: 116-7.
31. SrivastaMD, Alexander F, Tuthill RJ. Immunology of cutaneous vasculitis associated with both etanercept and infliximab. Scand J Immunol 2005; 61: 329-36.
32. Chan JL, Davis-Reed L, Kimball AB. Counter-regolatory balance: Atopic dermatitis in patients under infliximab infusion therapy. J Drugs Dermatol 2004; 3: 315-8.
33. Vena GA, Cassano N. Anti-tumor necrosis factor therapies for psoriasis. Exp Rev Dermatol 2007; 2: 335-49.
34. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action. Arthritis Rheum 2008; 59: 996-1001.
35. Hassan AS, Simon D, Simon HU, Braathen LR, Yawalkar N. Efalizumab-associated papular psoriasis. Arch Dermatol 2007; 143: 900-6.
36. Raptivar - Summary of product Characteristics (EMEA - Rev. 6, published on 28/02/2008).
37. Fargnoli MC, Tabilio A, Coletti G, Peris K. Efalizumab-induced immune thrombocytopenia during retreatment. J Am Acad Dermatol 2008; 58(5 Suppl 1): S125-7.
38. Kwan JM, Reese AM, Trafeli JP. Delayed autoimmune hemolytic anemia in efalizumab-treated psoriasis. J Am Acad Dermatol 2008; 58: 1053-5.
39. Chan ATY, Cleeve V, Daymond TJ. Necrotising fascitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J 2002; 78: 47-8.
40. Campi P, Benucci M, Manfredi M, Demoly P. Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-alpha antagonists. Curr Opin Allergy Clin Immunol 2007; 7: 393-403.
41. D'Arcy CA, Mannik M. Serum-sickness secondary to treatment with murine human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum 2001; 44: 1717-8.
42. Herishanu Y. Rituximab induced serum-sickness. Am J Hematol 2002; 70: 329.
43. Hellstedt B, Ahmed A. Delayed type hypersensitivity reaction or serum-sickness after rituximab treatment. Ann Oncol 2003; 14: 1792.
44. Dereure O, Navarro R, Rossi JF, Guilhou JJ. Rituximab induced vasulitis. Dermatology 2001; 203: 83-4.
45. Kandula P, Kouides PA. Rituximab induced leukocytoclastic vasculitis: A case report. Arch Dermatol 2006; 142: 246-7.
46. Proctor L, Benzulli B, Warren S, Brecher M. Monoclonal antibody stimulated serum- sickness. Transfusion 2004; 44: 955.
47. Krishnan RS. Serum-sickness due to infliximab in a patient with psoriasis. J Drugs Dermatol 2004; 3: 305-8.
48. Chefietz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: A large center experience. Am J Gastroenterol 2003; 98: 1315-24.
49. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
50. Pilette C, Coppens N, Houssiau F, Rodenstein DO. Severe serum sickness-like syndrome after omalizumab therapy for asthma. J Allergy Clin Immunol 2007; 120: 972-3.
51. Hellwig K, Schimrigk S, Fischer M, Haghikia A, Müller T, Chan A, et al. Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch Neurol 2008; 65: 656-8.
52. Hanauer SB. Safety of infliximab in clinical trials: A review. Aliment Pharmacol Ther 1999; 13 (Suppl 4): 16-23.
53. De Rycke L, Kruithof E, Van Damme N, Hoffmann IE, Van de Bossche N, Van de Bossche F, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthr Rheum 2003; 48: 1015-23.
54. Kugathasan S, Levy MB, Saeian K, Vasilopoulos S, Kim JP, Prajapati D, et al. Infliximab retreatment in adults and children with Crohn's disease: Risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 2002; 97: 1408-14.
55. Riegert-Johnson DL, Godfrey JA, Myers JL, Hubmayr RD, Sandborn WJ, Loftus EV jr. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflamm Bowel Dis 2002; 8: 186-91.
56. Baudouin V, Cusiak A, Hadad E, Schandene L, Goldman M, Loirat C, et al. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interlekin-2-receptor monoclonal antibody basiliximab. Transplantation 2003; 76: 459-63.
57. Leonard PA, Woodside KJ, Gugliuzza KK, Sur S, Daller JA. Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody. Transplantation 2002; 74: 1697-700.
58. Hawkins C, Gatenby P, McGill D. Severe hypotension complicating primary angioplasty: Allergy to abciximab. Allergy 2003; 58: 688-9.
59. Pharand C, Palisaltis DA, Hamel D. Potential anaphylactic shock with abciximab readministration. Pharmacotherapy 2002; 22: 380-3.
60. Guzzo JA, Nichols TC. Possible anaphylactic reaction to abciximab. Cathet Cardiovasc Interv 1999; 48: 71-3.
61. Iakovou Y, Manginas A, Melissari E, Cokkinos DV. Acute profound thrombocytopenia associated with anaphylactic reaction after abciximab therapy during percutaneous coronary angioplasty. Cardiology 2001; 95: 215-6.
62. Soykan I, Ertam C, Ozden A. Severe anaphylactic reaction to infliximab: report of a case. Am J Gastroenterol 2000; 95: 2395-6.
63. Diamante A, Castro M, Papadatou B, Ferretti F, Gambarara M. Severe anaphylactic reaction to infliximab in pediatric patients with Crohn's disease. J Pediatr 2002, 140:636-7.
64. Domm A. A patient reaction to infliximab. Ann Allergy Asthma Immunol 2003; 90: 298-301.
65. Chavez-Lopez MA, Delgado-Villafrana J, Gallaga A, Huerta-Yanez G. Severe anaphylactic reaction during the second infusion of infliximab in a patient with psoriatic arthritis. Allergol Immunopathol 2005; 33: 291-2.
66. Dreyfus DH, Randolph CC. Characterization of an anaphylactoid reaction to omalizumab. Ann Allergy Asthma Immunol 2006; 96: 624-7.
67. Chipps B. Systemic reaction to omalizumab. Ann Allergy Asthma Immunol 2006; 97: 267.
68. Price KS, Hamilton RG. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc 2007; 28: 313-9.
69. Limb SL, Starke PR, Lee CE, Chowdhury BA. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 2007;120: 1378-81.
70. Chung CH, Chan E, Berlin J, Gilbert J, Yarbrough W, Satinover S, et al. Cetuximab-related hypersensitivity reactions associated with pre-existing cetuximab-specific IgE antibody. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 2007; 25 (Suppl 18): 9097 (abstr.).
71. Bennett AN, Wong M, Zain A, Panayi G, Kirkham B. Adalimumab induced asthma. Rheumatology 2005; 44: 1199-200.
72. George SJ, Anderson HL, Hsu S. Adalimumab-induced urticaria. Dermatol Online J 2006; 12: 4.
73. Bergamaschini L, Santangelo T, Faricciotti A, Ciavarella N, Mannucci PM, Agostoni A. Study of complement-mediated anaphylaxis in humans. The role of IgG subclasses (IgG1 and/or IgG4) in the complement-activating capacity of immune complexes. J Immunol 1996;1 56: 1256-61.
74. Bircher AJ, Hédin H, Berglund A. Probable grade IV dextran-induced anaphylactic reaction despite hapten inhibition. J Allergy Clin Immunol 1995; 95: 633-4.
75. Kraft D, Hedin H, Richter W, Scheiner O, Rumpold H, Devey ME. Immunoglobulin class and subclass distribution of dextran-reactive antibodies in human reactors and non reactors to clinical dextran. Allergy 1982; 37: 481-9.
76. Bircher AJ, Czendlik CH, Messmer SL, Müller P, Howald H. Acute urticaria caused by subcutaneous recombinant hirudin: Evidence for an IgG-mediated hypersensitivity reaction. J Allergy Clin Immunol. 1996; 98 (5 Pt 1): 994-6.
77. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003; 108: 2062-5.
78. Adourian U, Shampaine EL, Hirshman CA, Fuchs E, Adkinson NF Jr. High-titer protamine-specific IgG antibody associated with anaphylaxis: report of a case and quantitative analysis of antibody in vasectomized men. Anesthesiology 1993; 78: 368-72.
79. Weiss ME, Nyhan D, Peng ZK, Horrow JC, Lowenstein E, Hirshman C, et al. Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine. N Engl J Med 1989; 320: 886-92.
80. Hinoda Y, Sasaki S, Ishida T, Imai K. Monoclonal antibodies as effective therapeutic agents for solid tumors. Cancer Sci 2004; 95: 621-5.
81. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory colorectal cancer. N Engl J Med 2004; 351: 337-45.
82. O'Neil BH, Allen R, Spigel AD, Stinchcombe TE, Moore DT, Berlin JD, et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 2007; 25: 3644-8.
83. Bush RB, Wood RA, Eggleston PA. Laboratory animal allergy. J Allergy Clin Immunol 1998; 102: 99-108.
84. Park A, Edwards M, Donaldson M, Ghatei M, Meeram K. Interfering antibodies affecting immunoassay in woman with pet rabbits. Br Med J 2003; 326: 541-2.
85. Hawkins BR, Saueracker GC, Dawkins RL, Davey MG, O'Connor KJ. Population study of heterophile antibodies. Vox Sang 1980; 39: 339-42.
86. Matsui EC, Simon E, Rand C, Butz A, Buckley TJ, Breysse P, et al. Airborne mouse allergen in the home of inner-city children with asthma. J Allergy Clin Immunol 2005; 115: 358-63.
87. Matsui EC, Wood RA, Rand C, Kanchanaraksa S, Sartz L, Eggleton PA. Mouse allergen exposure and mouse skin prick sensitivity in suburban middle-class children with asthma. J Allergy Immunol 2004; 113: 910-5.
88. Platts-Mills TA, Satinover SM, Naccara L, Litonjua AA, Phipatanakul W, Carter MC, et al. Prevalence and titers of IgE antibodies to mouse allergens. J Allergy Clin Immunol 2007; 120: 1058-64.
89. Siraganian R, Sandberg A. Characterization of mouse allergens. J Allergy Clin Immunol 1979; 63: 435-42.
90. Price JA, Longbottom J. Allergy to mice. Further characterization of two major mouse allergens (Ag 1 and Ag 3) and immuno-histochemical investigations of their sources. Clin Exp Allergy 1990; 20: 71-7.
91. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactosealpha-1,3-galactose. N Engl J Med 2008; 358: 1109-17.
92. Moneret-Vautrin DA, Morisset M, Vignaud JM, Kanny G. T-cell mediated allergy to abciximab. Allergy 2002; 57: 269-70.
93. Varghese M, Liebermann P. The effects of repeated omalizumab administration on skin test positivity and the assessment of the safety of administration in patients with positive skin tests to mouse antigen. Allergy Asthma Proc 2007; 28: 320-3.
94. Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs 2004; 64: 1767-77.
95. Duhen C, Dicato MA, Ries F. Side-effects of intravenous immunoglobulins. Clin Exp Immunol 1994; 97 (Suppl 1): 79-83.
96. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Therapeutic efficacy of multiple intravenous infusions of anti tumor necrosis factor alpha monoclonal antibody combined with low doses weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.
97. Baert F, Norman M, Vemeire S, Van Assche G, D'Haenz G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8.
98. Menter A, Feldman SR, Weinstein G, Papp K, Evans R, Guzzo C, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plEque psoriasis. J Am Acad Dermatol 2007; 56: 31: e1-15.
99. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity and associated infusion reactions. Mount Sinai J Med 2005; 72: 250-6.
100. Stallmach A, Giese T, Schmidt C, Meuer SC, Zeuzem SS. Severe anaphylactic reaction to infliximab: Successful treatment with adalimumab. Eur J Gastroenterol Hepatol 2004; 16: 627-30.
101. Youdim A, Vasiliauskas EA, Targan SR, Papadakis KA, Ippoliti A, Dubinsky MC, et al. A pilot study of adalimumab in infliximab allergic patients. Inflamm Bowel Dis 2004; 10: 333-8.
102. Nestorov I. Clinical pharmacokinetics of Tumor Necrosis Factor Antagonists. J Rheumatol 2005; 32 (Suppl 74): 13-8.
103. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: The relationship with anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921-6.
104. Georgitis JW, Bowniing MC, Steiner D, Lorentz WB. Anaphylaxis and desensitization to the murine monoclonal antibody used for renal graft rejection. Ann Allergy 1991; 66: 343-6.
105. Puchner TC, Kugathasan S, Kelly KJ, Binion DG. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflamm Bowel Dis 2001; 7: 34-7.
106. Bangash S, Kaufman D, Moissidis S, Mahmoud S, Jordan P, Bahna SL. Infliximab desensitization. J Allergy Clin Immunol 2005; 115: S 180 (abstr.).
107. Smedley M, Plevy S, Mayer I. Desensitization protocol for infliximab use in Crohn patients with prior reactions. Gastroenterology 2004; W2350: A-615 (abstr.).
108. Saadeh C, McGee M, Malacara J, Gaylor M. Desensitization with infliximab following anaphylaxis in a patient with rheumatoid arthritis. Ann Eur Congress Rheumatol Stokholm 2002; FR10148 (abstr.).
109. Duburque C, Lelong J, Iacob R, Seddik M, Desreumaux P, Fournier C, et al. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions. Aliment Pharmacol Ther 2006; 24: 851-8.
110. Melamed J, Stahlman JE. Rapid desensitization and rash immunotherapy to trastuzumab (Herceptin). J Allergy Clin Immunol 2002; 110: 813-4.
111. Adachi Y, Yoshio-Hoshino N, Nishimoto N. The blockade of IL-6 signaling in rational drug design. Curr Pharm Des 2008; 14(12): 1217-24.
112. Bjelogrlic SK, Radulovic S, Babovic N. Molecular targeting agents in renal cell carcinoma: Present strategies and future perspectives. Curr Pharm Des 2008; 14(11): 1058-77.
113. Ishino T, Harrington AE, Gopi H, Chaiken I. Structure-based rationale for interleukin 5 receptor antagonism. Curr Pharm Des 2008; 14(12): 1231-9.